TriangleNCT01812252 · OUTCOME
Number of Patients Who Relapse Post-transplant
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 18 months
What was measured
To compare which of the two, intensive chemotherapy versus hypomethylating agent-based therapy, have a factor of relapse post hematopoietic cell transplantation (HCT).
Analysis population: Only participants who received a HCT that relapse were assessed for this outcome.
Groups in this outcome
Arm A (Decitabine or Azacitidine)
Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity. Azacitidine (AZC): Given IV or SC Decitabine: Given IV or SC Quality-of-Life Assessment: Ancillary studies
Arm B (Induction-like Chemotherapy Regimen)
Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only. Quality-of-Life Assessment: Ancillary studies
| Group | Source count |
|---|---|
| Arm A (Decitabine or Azacitidine) | 12 |
| Arm B (Induction-like Chemotherapy Regimen) | 13 |
Reported measurements
Source class 1
Relapse post HCT
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A (Decitabine or Azacitidine) | 6 | Not reported | Not reported | Not reported | Not reported |
| Arm B (Induction-like Chemotherapy Regimen) | 3 | Not reported | Not reported | Not reported | Not reported |
Did not relapse post HCT
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm A (Decitabine or Azacitidine) | 6 | Not reported | Not reported | Not reported | Not reported |
| Arm B (Induction-like Chemotherapy Regimen) | 10 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 3
- title
- Relapse post HCT
- measurements
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 10
- title
- Did not relapse post HCT
- denoms
- counts
- group Id
- OG000
- value
- 12
- group Id
- OG001
- value
- 13
- units
- Participants
- description
- To compare which of the two, intensive chemotherapy versus hypomethylating agent-based therapy, have a factor of relapse post hematopoietic cell transplantation (HCT).
- groups
- description
- Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity. Azacitidine (AZC): Given IV or SC Decitabine: Given IV or SC Quality-of-Life Assessment: Ancillary studies
- id
- OG000
- title
- Arm A (Decitabine or Azacitidine)
- description
- Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only. Quality-of-Life Assessment: Ancillary studies
- id
- OG001
- title
- Arm B (Induction-like Chemotherapy Regimen)
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Only participants who received a HCT that relapse were assessed for this outcome.
- reporting Status
- POSTED
- time Frame
- Up to 18 months
- title
- Number of Patients Who Relapse Post-transplant
- type
- SECONDARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice